...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma
【24h】

Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma

机译：基质金属蛋白酶2（MMP-2）与乳腺癌的生存有关

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Adjuvant therapy is one of the major advances in the treatment of breast carcinoma patients – but do all patients need it? New predictive markers, which are able to save breast carcinoma patients from the most toxic adjuvant therapies, are still needed. The expression of matrix metalloproteinases (MMP-2) has been previously linked to invasiveness of carcinoma cells. In this study, we explored the role of MMP-2 as a prognostic factor in breast carcinoma in a large series to be able to show the favourable effect of MMP-2 negativity in poor prognosis subgroup of hormone receptor-negative patients. The MMP-2 immunoreactive protein was evaluated from primary adenocarcinoma of the breast in 453 cases by using a specific monoclonal antibody in immunohistochemical stainings. The MMP-2 protein found in breast carcinoma tumour cells was here shown to be associated with a shortened recurrence-free survival or relative overall survival (P=0.03). It was shown here that MMP-2 negativity is significantly linked to favourable prognosis in patients considered to be at risk due to their hormone receptor negativity. In the patient group presenting with a progesterone receptor-negative tumour, the survival rate of the MMP-2-positive cases was 58% while it was 95% in MMP-2-negative cases after 10 years of follow-up (P=0.005). The present data shows for the first time that MMP-2 negativity could serve as a marker for favourable prognosis in breast carcinoma patients with a hormone receptor-negative tumour usually associated with high risk. MMP-2 is also shown to correlate to shortened survival independent of major prognostic indicators in patients with primary breast carcinoma.
机译：辅助治疗是乳腺癌患者治疗的主要进展之一，但是所有患者都需要吗？仍然需要能够将乳腺癌患者从最具毒性的辅助治疗中拯救出来的新的预测标记。基质金属蛋白酶（MMP-2）的表达先前已与癌细胞的侵袭性相关。在这项研究中，我们探索了MMP-2作为乳腺癌预后因素的作用，从而能够证明MMP-2阴性在激素受体阴性患者的不良预后中具有良好的作用。通过在免疫组织化学染色中使用特异性单克隆抗体，在453例乳腺原发性腺癌中评估了MMP-2免疫反应蛋白。此处显示在乳腺癌肿瘤细胞中发现的MMP-2蛋白与缩短的无复发生存期或相对总体生存期相关（P = 0.03）。在此表明，由于激素受体阴性，被认为有风险的患者中，MMP-2阴性与预后良好相关。患有黄体酮受体阴性肿瘤的患者组，随访10年后，MMP-2阳性病例的存活率为58％，而MMP-2阴性病例的存活率为95％（P = 0.005）。本数据首次显示，MMP-2阴性可作为乳腺癌患者（通常伴有高风险）的激素受体阴性肿瘤的良好预后指标。在患有原发性乳腺癌的患者中，MMP-2还显示出与缩短的生存时间相关，而与主要预后指标无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号